Visit statistics

May our host count your visit? It then sets a cookie and notes the pages you read, your device and your country. We see only totals. The site works the same either way. What is recorded

Peptides Explained

Skin and hair

GHK-Cu

A copper-carrying peptide used in skin creams. No published study has tested injecting it in people.

Not an authorised medicine

Short page. This is a short page. A full page with the complete evidence review is planned for version 1.1. The grades and regulatory status below are complete and sourced.

At a glance

Is it an approved medicine?
No Not approved as a medicine in the EU, the UK or the US.
Has it been tested in people?
Some Small trials in patients. No large trials published yet.
Is it allowed in sport?
Unclear Not named on the anti-doping list. Ask your anti-doping organisation before using it in sport. Regulatory status
What is the biggest risk?
No published tests of shots in people. Vials may carry germs. More about the risks

Status checked on . The details and sources are further down this page.

Stop and get help if you notice

  • Hot, red, swollen or painful injection site29
  • Fever or chills after you inject it52
  • Swollen face or throat, or trouble breathing53,9

If it is severe, call your local emergency number.

All warning signs, further down this page Warning signs for any peptide

The 30-second version

About 5 minutes for the short version; 10 with every detail open.

  • GHK-Cu is a tiny peptide of three amino acids holding copper. It occurs in human blood.
  • EU skin creams may contain it. It is not an approved medicine in the EU or the US.
  • Injecting it is something else. No published study in people has tested it as an injection.
  • Small studies of creams and gels on skin and wounds gave mixed results.
  • US advisers will discuss it by the end of February 2027. Their advice is not an approval.
Class
Skin and hair
Made of
Three amino acids holding one copper ion
Allowed in the EU
A cosmetic ingredient in skin products
Injected use
Not a cosmetic; no published studies in people
Studies in people
A few small trials of creams and gels
Status in the EU
Not authorised
Tested in people
Some

Label facts, not dosing advice. Sources are in the sections below.

Last reviewed
A slice of human skin under a microscope: a thin purple outer layer above a thicker, pale pink layer of fibres, with small clusters of cells from a harmless mole deeper down.
Human skin under the microscope. Cosmetics with GHK-Cu go on the top layer; injections go below the skin. Photo: Kilbad (Wikimedia Commons) Public domain Image details

Each section starts with the short answer. The rest is folded under “In detail”.

Evidence profile

Four separate questions. Not a score.

Human clinical evidence How far has it been tested in people?
Phase II (dose and early effect)
Preclinical volume How much laboratory and animal research exists?
Extensive
Source independence How many independent groups produced it?
Broadly replicated
Safety characterisation How well do we know the harms in humans?
Uncharacterised
In detail Why these grades: the reason for each step
Human clinical evidence
Phase 2 on our rubric, for use on the skin only: small randomised trials of a GHK-Cu gel on diabetic foot ulcers (number of patients not given in the abstract), a copper-tripeptide cream on leg ulcers (86 patients, no better than an inert cream) and skin care after laser treatment (13 patients, no objective difference). No published study has given GHK-Cu to people by injection.
Preclinical volume
Extensive. On 23 October 2026 PubMed held 171 non-review records on GHK-Cu, 64 of them mentioning animals, plus many cell studies.
Source independence
Broadly replicated. The discoverer, Loren Pickart, and the Reims group each appear on only 6 of those records; collagen and wound effects were reported by several unrelated groups.
Safety characterisation
Uncharacterised. Cell tests suggest little skin irritation and creams are widely sold, but there are no systematic human safety data, and none at all for injection.

We never add these up. A compound can have a large animal literature from one laboratory and no human data at all — that is a specific situation, and a single number would hide it. How we grade evidence

In detail The molecule: amino-acid sequence and technical details
Amino-acid sequence3 amino acids

H–Gly-His-Lys–OH · Cu(II)

Read from the N-terminus (start) to the C-terminus (end).

Modifications
position 2: The histidine helps hold one copper(II) ion
Full name
Glycyl-L-histidyl-L-lysine copper(II) complex
Also called
copper peptide, copper tripeptide-1, prezatide copper, GHK copper
Class
Skin and hair
Body systems
Skin

What it actually is

What is GHK-Cu?

A copper-carrying peptide found in blood. It is sold in skin creams and as injections.
A skin cream and an injection with GHK-Cu are not the same thing. What is known about each use, from EU law, the FDA and published studies, checked on 23 October 2026.
On the skin (cosmetic cream)Injected
Allowed in the EU?Yes Listed as a cosmetic ingredient, copper tripeptide-1.1No Anything injected is not a cosmetic, and no medicine with GHK-Cu is authorised.2,3
Studied in people?Yes A few small trials, with mixed results.4,5,6No No published study.7
Known safety concerns?Unknown Little data; low skin irritation in cell tests.8Unknown The FDA warns of possible immune reactions from clumps and impurities.9

Loren Pickart found the factor in human blood in 1973; it was identified as glycyl-histidyl-lysine (GHK) in 1977, and shown to bind copper in 1980.10,11,12

In detail The molecule, and a wound gel from the 1990s

GHK-Cu is Gly-His-Lys holding one copper(II) ion. PubChem gives the complex as C14H23CuN6O4+, mass 402.92 g/mol; the peptide alone is C14H24N6O4, 340.38 g/mol.13 Other names include prezatide copper and, on cosmetic labels, copper tripeptide-1.13,1

In the 1990s a GHK-Cu gel, called “lamin Gel” in the trial report, was tested on diabetic foot ulcers.4 A wound dressing named Iamin Gel was cleared in the US in 1996 as a medical device. That is a different route from approval as a medicine.14

Proposed mechanism

How does it work?

In cells it carries copper and boosts collagen. Whether this matters in people is unclear.
The proposed causal chain, step by step

Each step is labelled with how well the link from the previous step is established.

  1. Step 1 Binding In cells

    Holds copper and carries it into cells

    GHK binds copper(II) tightly. In liver cancer cells grown in a dish, it increased how much copper the cells took up (1980).

  2. Step 2 Cell response In cells

    Skin repair cells make more collagen

    In cultures of fibroblasts, the cells that make collagen, GHK-Cu raised collagen production at very low concentrations.

  3. Step 3 Tissue response In animals

    More repair tissue in rat wounds

    In rats, GHK-Cu injected into wound chambers under the skin increased collagen and other repair tissue; a control tripeptide did not.

  4. Step 4 Effect on the body In humans

    Better healing or younger skin in people: mixed

    One gel trial on diabetic foot ulcers reported faster closure; a leg-ulcer trial and a laser-skin trial found no objective benefit. Injected use has not been studied.

In detail What each step rests on

The copper and collagen steps come from cells in a dish, the repair-tissue step from rats.12,15,16 On the skin, GHK-Cu passes the waterproof outer layer poorly, and how much reaches deeper layers has been little studied.17,18 In 1980 the discoverers noted effects in cultured cells that ranged “from the stimulation of growth and differentiation to outright toxicity”.12

What the evidence actually shows

Does it work?

For skin and wounds, small trials gave mixed results. Injections have never been tested.

One gel trial on foot sores was positive

98.5%

median ulcer closure with the gel, against 60.8% with a dummy gel

Who took part Mulder 1994: multicentre, evaluator-blinded trial; patient numbers not given in the abstract Source Mulder et al. (1994)4 Evidence Human trials

On leg ulcers, the copper cream did no better than an inert cream

86

patients with leg ulcers compared three creams

Who took part Bishop 1992: randomised, evaluator-blinded trial Source Bishop et al. (1992)5 Evidence Human trials

After a skin laser, experts saw no change

13

patients finished; only they rated their skin better

Who took part Miller 2006: randomised trial after laser skin resurfacing Source Miller et al. (2006)6 Evidence Human trials

Most research is in cells and animals, from many groups.7 A trial of a GHK-Cu gel on small skin wounds in 60 healthy adults started in 2026.19

In detail Every study in one table

7 studies: 3 in humans, 1 in animals, 3 in cells, 0 reviews or other.

Studies discussed on this page
Study Species n Design Funding Research group What it found What it did not show
Pickart & Thaler 1973 10 Cells (lab) not reported Laboratory (cells) Not disclosed Originating group A small factor in human blood serum helped normal liver cells survive in culture and made liver cancer cells grow. Liver cells in a dish; the factor was identified as Gly-His-Lys only in 1977.
Maquart et al. 1988 15 Cells (lab) not reported Laboratory (cells) (controlled) Not disclosed Mixed GHK-Cu raised collagen production by fibroblasts in culture, at very low concentrations and without changing cell numbers. Cells in a dish; co-authored by the discoverer.
Bishop et al. 1992 5 Humans 86 Randomised controlled trial (controlled, blinded) Not disclosed Independent group In 86 patients with leg ulcers caused by poor vein function, a copper-tripeptide cream did no better than an inert cream; a silver cream did better than both. The abstract does not name the tripeptide; leg ulcers are not foot ulcers.
Maquart et al. 1993 16 Rats not reported Animal experiment (controlled) Not disclosed Independent group In rats with wound chambers implanted under the skin, GHK-Cu increased collagen, protein and DNA in the chamber, depending on the concentration. An artificial wound model in rats; no healing time or scar outcome in a natural wound.
Mulder et al. 1994 4 Humans not reported Randomised controlled trial (controlled, blinded) Not disclosed Independent group With standard wound care, a GHK-Cu gel closed plantar diabetic foot ulcers further than a dummy gel (median 98.5% against 60.8%) and infections were less common. The abstract gives no number of patients and no funder; a single trial that we could not find repeated.
Miller et al. 2006 6 Humans 13 Randomised controlled trial (controlled, blinded) Not disclosed Independent group After laser skin resurfacing, blinded experts and computer analysis found no difference in redness, wrinkles or skin quality with GHK-Cu skin care; patients rated their skin better. Only 13 patients completed; patient ratings were not blinded measures.
Hostynek et al. 2011 18 Cells (lab) not reported Laboratory (cells) Not disclosed Independent group On donated human skin in a lab device, copper from GHK-Cu passed through the skin over 48 hours, and some stayed in it. Isolated skin, not a living person; the lab set-up used a large, constant amount.

None of these trials used injections, and most are decades old. Claims about hair growth, wrinkles or whole-body “repair” rest on cell, animal or small cosmetic studies, not on controlled trials of injected GHK-Cu.7

Regulatory status

Is it legal?

In EU skin creams, yes. As an injection it is not an approved medicine.
OK in skin creams. Not approved as a medicine. Status in the Netherlands, the EU and the US, and in sport, checked on 23 October 2026.
Netherlands and the EUUnited States
Approved as a medicine?No No EU or Dutch authorisation.3,20No Not FDA-approved.21
Allowed in cosmetics?Yes As copper tripeptide-1, with no special limits listed.1Unknown We did not check US cosmetic rules.
Allowed in sport?Unknown Not named. It may fall under S0, the ban on unapproved substances.22,23Unknown The same worldwide rule.22
In detail Status in each country, and in sport
Regulatory status by jurisdiction
Jurisdiction Status Note Checked
European Union Not authorised No medicine. Allowed as a cosmetic ingredient ('copper tripeptide-1'); a product meant for injection cannot be a cosmetic. 3,54,1,2
Netherlands Not authorised No medicine in the CBG database. Supplying a medicine without a marketing authorisation is prohibited. 20,24
United States Not authorised Not FDA-approved. Injectable GHK-Cu was in category 2 (nomination withdrawn); other routes under evaluation; advisory meeting due by end of February 2027. 21,26,9,27
Sport (WADA) Unclear (not named) Unclear: not named on the List. S0 may apply because it is not an approved medicine, but no anti-doping body has ruled. Ask your anti-doping organisation. 22,23,25,14

All statuses were checked on 23 October 2026. Under EU law a cosmetic is put on the outside of the body, and anything meant to be injected is not a cosmetic.2 Dutch law forbids supplying a medicine without a marketing authorisation, with narrow exceptions.24

In sport, GHK-Cu is not named on the 2026 or 2027 List. The S0 class bans substances that no government health authority has approved for treatment, and the 2027 List adds “peptides” to its examples. WADA notes that a peptide not named on the List may still be banned.22,23,25 No medicine with GHK-Cu is approved, but a gel dressing was cleared as a device, and WADA has not ruled.14 Athletes should ask their anti-doping organisation before using any form.

In detail The United States: pharmacy compounding

The FDA placed injectable GHK-Cu in category 2, for substances that may pose significant safety risks, citing possible immune reactions and “limited data in humans”; that nomination was withdrawn.9 GHK-Cu for other routes is in category 1, still under evaluation.26 The FDA plans to ask its Pharmacy Compounding Advisory Committee about GHK-Cu before the end of February 2027.27 Such a vote is advice only. A listing would allow US pharmacies to compound it on prescription; it would not be a marketing authorisation and would change nothing in the EU.28

Risk profile

What are the risks?

On skin, few problems are known. Injected, its effects are unknown and the product may be impure.
The main risks of injecting it come from what is unknown. What the FDA and the published studies say, as of 23 October 2026.
Possible harmShown in people?
An immune reaction to the peptide, its clumps or impuritiesUnknown The FDA’s concern for injected forms; not studied.9
Infection from germs in a non-sterile productUnknown Not studied for GHK-Cu; a known risk of any unsterile injection.29
Skin irritation from creamsUnknown Low in cell tests; no systematic human data.8
In detail Why the gaps matter

GHK-Cu changes how cells take up copper. In early cell work, its effects ranged from more growth to outright toxicity, depending on the type of cell.12 We found no study that measured what an injection does to copper levels, the liver or other organs in people.7 The FDA found “limited data in humans” to judge the safety of injections.9 See product risk.

If someone is going to do this anyway

This section exists to reduce harm. It gives no doses, schedules or sourcing advice, and it is not a recommendation to use this compound.

How can someone lower the risk?

Check the product first, keep creams on the skin, and know when to stop.

If your product did not come from a pharmacy: check before you use it

These checks can show that something is wrong. None of them can show that a product is good or free of germs.30,31,32

Tick each box when you have checked it.

  • The seal and the vial are whole

    A broken cap or seal, or a cracked vial, can let germs in. Then do not use it.33,34,35

  • The label shows the name, amount, batch number and expiry date

    In the EU, a medicine must show all four, even on a small vial. If one is missing, or the date has passed, that is a warning sign. Take a photo of the label.36,33

  • For GHK-Cu

    Check what the label says the product is for. Cosmetic GHK-Cu is made for the skin. Under EU law, nothing meant for injection is a cosmetic.2,1

  • It looks right

    A liquid, or a powder after mixing, should be clear and colourless, with no bits. Is it cloudy, has it changed colour, or do you see bits? Then do not use it.37,38

  • A lab report proves little if:

    • its batch number is not the one on your vial;
    • it does not name the lab, or has no date or signature;
    • it shows only purity (HPLC), with no test of what it is, such as mass spectrometry;
    • it has no test for germs (sterility) or for toxins from germs (endotoxin).

    Even a full report covers only one sample. A report from the seller comes from someone who gains if it looks good. It cannot show that your vial is clean.39,40,41,42,43

    What a certificate of analysis shows, and what it does not

  • It was kept as the label says

    Heat, freezing and sunlight can damage a peptide. Did it arrive warm, or was it frozen? Then do not use it. Often nobody can tell you how it was kept on the way. If you cannot know, you cannot rule out damage. When in doubt, throw it out.38,44,45,35

    When to throw a vial away

  • Clean steps, and a new sterile needle and syringe every time

    Wash your hands and wipe the rubber top with alcohol. Never share a needle, a syringe or a vial.35,46,44

    Sterile technique, step by step

  • Keep the vial, its label and any papers

    Keep them, even when the vial is empty, until you know you feel well. If you need a doctor, bring them. A lab can test what was inside.47,48

    If something goes wrong

  • Tell a doctor, and agree which checks fit you

    A doctor can help you choose blood tests that fit what you use. In the Netherlands, your doctor must keep what you say private.49,50,51

    Which checks matter, and whyTalking to your doctor

  • Know the warning signs before you start

    Spreading redness, fever, a swollen face or hard breathing need help fast. If it is severe, call your local emergency number.29,52,53

    All warning signs, and how fast to act

When to stop and get help

Sources 29, 52, 53, 9

Stop-now warning signs

Call your local emergency number now

  • Confusion or slurred speech, very fast breathing, or pale, blue or blotchy skin, often with fever or shivering These can be signs of sepsis: the body's reaction to an infection has started to damage its own organs.
  • Fainting and not waking up within a minute, or fainting with chest pain, a racing heart or a fit This can be a dangerous heart rhythm or a severe allergic reaction.
  • Pain at the injection spot that is much worse than it looks, or dark, purple or grey patches or blisters there This can be a rare, fast-spreading infection of the deep layers under the skin (necrotising fasciitis).
  • Swelling of the lips, tongue or throat, trouble breathing or swallowing, wheezing, a hoarse voice, or feeling faint, soon after an injection This can be a severe allergic reaction (anaphylaxis), which is life-threatening and gets worse very quickly.

Get medical help today

  • Fever, shivering or feeling very ill in the days after an injection Germs from the needle, the skin or the product may have reached your blood. If you also have a fast heartbeat or fast breathing, call your local emergency number.
  • Redness, heat, swelling or pain around the injection spot that keeps growing or getting worse This can be a skin infection (cellulitis), which needs antibiotics before it spreads.
  • Red lines that run from the injection spot towards the armpit or groin The infection may be spreading along the lymph vessels, and from there into the blood. If you also have a fever with a fast heartbeat or fast breathing, call your local emergency number.
  • A painful, warm lump that fills with pus This is probably an abscess: it often needs draining by a doctor, so do not squeeze it.
  • You were pricked by a needle that someone else had used Blood on a used needle can pass on HIV and hepatitis B or C, and preventive treatment works best within hours.

Stop and contact a doctor

  • You fainted, but woke up quickly and now feel well Fainting is often harmless, but a doctor should check the cause.
  • A new mole, or a mole that changes size, shape or colour, itches or bleeds A changing mole can be skin cancer, and tanning peptides such as melanotan II have been linked to new and changing moles in case reports.
  • A lump at an injection spot that does not go away, or keeps growing A doctor should check whether it is an abscess, a reaction to the product or something else.
  • An itchy, raised rash, or puffy eyes or lips, while breathing stays normal Your body may be reacting to the product, and using it again can bring the reaction back.
In detail Checks that make sense

A doctor can help you decide which checks fit you (see talking to your doctor). Tell them about any product you use, including creams. Watch the skin where you put it: a rash that spreads or does not settle is a reason to stop. For injecting, see sterile technique.

Sources

Every claim on this page links to one of these sources. Scholarly sources link to their DOI; regulatory sources to the regulator's own page.

In detail All 54 sources, numbered as in the text
  1. European Commission, DG Internal Market, Industry, Entrepreneurship and SMEs (2026). CosIng – Cosmetic ingredient database: COPPER TRIPEPTIDE-1 (substance ID 55687). Regulator ec.europa.eu — accessed 23 October 2026 ↩
  2. European Parliament and Council of the European Union (2009). Regulation (EC) No 1223/2009 on cosmetic products, Article 2 (definitions). Official Journal of the European Union, L 342. Law eur-lex.europa.eu — accessed 23 October 2026 ↩
  3. European Medicines Agency (2026). Medicines data download (JSON report of all EPARs: authorised, refused, withdrawn and suspended medicines). Dataset ema.europa.eu — accessed 20 October 2026 ↩
  4. Mulder GD, Patt LM, Sanders L, Rosenstock J, Altman MI, Hanley ME, Duncan GW (1994). Enhanced healing of ulcers in patients with diabetes by topical treatment with glycyl-l-histidyl-l-lysine copper. Wound Repair and Regeneration 2:259-269. Research article doi:10.1046/j.1524-475X.1994.20406.x ↩
  5. Bishop JB, Phillips LG, Mustoe TA, VanderZee AJ, Wiersema L, Roach DE, Heggers JP, Hill DP Jr, Taylor EL, Robson MC (1992). A prospective randomized evaluator-blinded trial of two potential wound healing agents for the treatment of venous stasis ulcers. Journal of Vascular Surgery 16:251-257. Research article doi:10.1067/mva.1992.37086 ↩
  6. Miller TR, Wagner JD, Baack BR, Eisbach KJ (2006). Effects of topical copper tripeptide complex on CO2 laser-resurfaced skin. Archives of Facial Plastic Surgery 8:252-259. Research article doi:10.1001/archfaci.8.4.252 ↩
  7. National Library of Medicine (2026). PubMed searches for GHK-Cu, 23 October 2026. PubMed. Dataset pubmed.ncbi.nlm.nih.gov — accessed 23 October 2026 ↩
  8. Li H, Toh PZ, Tan JY, Zin MT, Lee CY, Li B, Leolukman M, Bao H, Kang L (2016). Selected Biomarkers Revealed Potential Skin Toxicity Caused by Certain Copper Compounds. Scientific Reports 6:37664. Research article doi:10.1038/srep37664 ↩
  9. U.S. Food and Drug Administration (2026). Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks. Regulator fda.gov — accessed 20 October 2026 ↩
  10. Pickart L, Thaler MM (1973). Tripeptide in human serum which prolongs survival of normal liver cells and stimulates growth in neoplastic liver. Nature: New Biology 243:85-87. Research article PMID 4349963 ↩
  11. Schlesinger DH, Pickart L, Thaler MM (1977). Growth-modulating serum tripeptide is glycyl-histidyl-lysine. Experientia 33:324-325. Research article doi:10.1007/BF02002806 ↩
  12. Pickart L, Freedman JH, Loker WJ, Peisach J, Perkins CM, Stenkamp RE, Weinstein B (1980). Growth-modulating plasma tripeptide may function by facilitating copper uptake into cells. Nature 288:715-717. Research article doi:10.1038/288715a0 ↩
  13. National Center for Biotechnology Information (2026). PubChem Compound Summary for CID 71587328, Prezatide copper (GHK-Cu, copper tripeptide-1). PubChem. Dataset pubchem.ncbi.nlm.nih.gov — accessed 23 October 2026 ↩
  14. U.S. Food and Drug Administration (2026). 510(k) Premarket Notification database: K953853, Iamin Gel Wound Dressing (ProCyte Corp.). Regulator accessdata.fda.gov — accessed 23 October 2026 ↩
  15. Maquart FX, Pickart L, Laurent M, Gillery P, Monboisse JC, Borel JP (1988). Stimulation of collagen synthesis in fibroblast cultures by the tripeptide-copper complex glycyl-L-histidyl-L-lysine-Cu2+. FEBS Letters 238:343-346. Research article doi:10.1016/0014-5793(88)80509-x ↩
  16. Maquart FX, Bellon G, Chaqour B, Wegrowski J, Patt LM, Trachy RE, Monboisse JC, Chastang F, Birembaut P, Gillery P, et al. (1993). In vivo stimulation of connective tissue accumulation by the tripeptide-copper complex glycyl-L-histidyl-L-lysine-Cu2+ in rat experimental wounds. The Journal of Clinical Investigation 92:2368-2376. Research article doi:10.1172/JCI116842 ↩
  17. Ogórek K, Nowak K, Wadych E, Ruzik L, Timerbaev AR, Matczuk M (2025). Are We Ready to Measure Skin Permeation of Modern Antiaging GHK-Cu Tripeptide Encapsulated in Liposomes?. Molecules 30:136. Review doi:10.3390/molecules30010136 ↩
  18. Hostynek JJ, Dreher F, Maibach HI (2011). Human skin penetration of a copper tripeptide in vitro as a function of skin layer. Inflammation Research 60:79-86. Research article doi:10.1007/s00011-010-0238-9 ↩
  19. U.S. National Library of Medicine, ClinicalTrials.gov (2026). NCT07437586: Topical GHK-Cu gel to accelerate re-epithelialisation of standardised acute skin wounds in healthy adults (phase 2, randomised, double-blind, vehicle-controlled, split-wound). Trial registration clinicaltrials.gov — accessed 23 October 2026 ↩
  20. College ter Beoordeling van Geneesmiddelen (CBG-MEB) (2026). Geneesmiddeleninformatiebank (database of medicines authorised in the Netherlands). Regulator geneesmiddeleninformatiebank.nl — accessed 20 October 2026 ↩
  21. U.S. Food and Drug Administration (2026). openFDA Drugs@FDA queries, 23 October 2026: prezatide, GHK, copper tripeptide, AOD-9604, AOD9604, hexarelin, examorelin, nicotinamide riboside, nicotinamide mononucleotide, nadide, nicotinamide adenine dinucleotide, elamipretide. openFDA. Dataset api.fda.gov — accessed 23 October 2026 ↩
  22. World Anti-Doping Agency (2025). World Anti-Doping Code International Standard: Prohibited List 2026. Regulator wada-ama.org — accessed 20 October 2026 ↩
  23. World Anti-Doping Agency (2026). World Anti-Doping Code International Standard: Prohibited List 2027 (in effect 1 January 2027). Regulator wada-ama.org — accessed 20 October 2026 ↩
  24. Staten-Generaal / Koninkrijk der Nederlanden (2007). Geneesmiddelenwet, artikel 40 (verbod op geneesmiddelen zonder handelsvergunning, en de uitzonderingen). wetten.overheid.nl (BWBR0021505), version in force from 9 September 2025. Law wetten.overheid.nl — accessed 22 October 2026 ↩
  25. World Anti-Doping Agency (2026). Summary of Major Modifications and Explanatory Notes, 2027 Prohibited List. Regulator wada-ama.org — accessed 22 October 2026 ↩
  26. U.S. Food and Drug Administration (2026). Bulk Drug Substances Nominated for Use in Compounding Under Section 503A of the Federal Food, Drug, and Cosmetic Act (categories 1–3), updated 14 May 2026. Regulator fda.gov — accessed 20 October 2026 ↩
  27. U.S. Food and Drug Administration (2026). Meeting of the Pharmacy Compounding Advisory Committee (early announcement: meeting before the end of February 2027). Regulator fda.gov — accessed 22 October 2026 ↩
  28. U.S. Food and Drug Administration (2026). Bulk Drug Substances Used in Compounding Under Section 503A of the FD&C Act. Regulator fda.gov — accessed 20 October 2026 ↩
  29. NHS (England) (2024). Cellulitis. Web page nhs.uk — accessed 20 October 2026 ↩
  30. Inspectie Gezondheidszorg en Jeugd (IGJ) (2026). Online medicijnen. Regulator igj.nl — accessed 22 October 2026 ↩
  31. Ashraf AR, Mackey TK, Vida RG, Kulcsár G, Schmidt J, Balázs O, Domián BM, Li J, Csákó I, Fittler A (2024). Multifactor Quality and Safety Analysis of Semaglutide Products Sold by Online Sellers Without a Prescription: Market Surveillance, Content Analysis, and Product Purchase Evaluation Study. Journal of Medical Internet Research 26:e65440. Research article doi:10.2196/65440 ↩
  32. Smith RM, Schaefer MK, Kainer MA, Wise M, Finks J, et al. (2013). Fungal infections associated with contaminated methylprednisolone injections. The New England Journal of Medicine 369:1598-1609. Research article doi:10.1056/NEJMoa1213978 ↩
  33. U.S. Food and Drug Administration (2020). BeSafeRx: Considering an Online Pharmacy?. Regulator fda.gov — accessed 22 October 2026 ↩
  34. Hospira, Inc. / DailyMed (National Library of Medicine) (2026). Sterile Water for Injection, USP: prescribing information. Official product information dailymed.nlm.nih.gov — accessed 20 October 2026 ↩
  35. World Health Organization (2010). WHO best practices for injections and related procedures toolkit (WHO/EHT/10.02). World Health Organization, Geneva. Report who.int — accessed 20 October 2026 ↩
  36. European Parliament and Council of the European Union (2001). Directive 2001/83/EC on the Community code relating to medicinal products for human use (consolidated text). Official Journal of the European Communities, L 311. Law eur-lex.europa.eu — accessed 20 October 2026 ↩
  37. U.S. Food and Drug Administration / DailyMed (National Library of Medicine) (2026). EGRIFTA SV (tesamorelin for injection): prescribing information and instructions for use. Official product information dailymed.nlm.nih.gov — accessed 20 October 2026 ↩
  38. European Medicines Agency (2026). Wegovy (semaglutide): EPAR — overview and product information. Official product information ema.europa.eu — accessed 20 October 2026 ↩
  39. European Medicines Agency (ICH) (2000). ICH Q7 Good manufacturing practice for active pharmaceutical ingredients (CPMP/ICH/4106/00). European Medicines Agency, scientific guideline. Regulator ema.europa.eu — accessed 22 October 2026 ↩
  40. European Medicines Agency, CHMP and CVMP (2025). Guideline on the Development and Manufacture of Synthetic Peptides (EMA/CHMP/CVMP/QWP/367182/2025). European Medicines Agency. Regulator ema.europa.eu — accessed 22 October 2026 ↩
  41. U.S. Food and Drug Administration (2026). FDA Briefing Document for BPC-157-Related Bulk Drug Substances (BPC-157 (free base) and BPC-157 acetate), Pharmacy Compounding Advisory Committee meeting, 23–24 July 2026. Regulator fda.gov — accessed 20 October 2026 ↩
  42. U.S. Food and Drug Administration (2026). FDA Briefing Document for TB-500-Related Bulk Drug Substances (TB-500 (free base) and TB-500 acetate), Pharmacy Compounding Advisory Committee meeting, 23–24 July 2026. Regulator fda.gov — accessed 20 October 2026 ↩
  43. Janvier S, Cheyns K, Canfyn M, Goscinny S, De Spiegeleer B, Vanhee C, Deconinck E (2018). Impurity profiling of the most frequently encountered falsified polypeptide drugs on the Belgian market. Talanta 188:795-807. Research article doi:10.1016/j.talanta.2018.06.023 ↩
  44. U.S. Food and Drug Administration (2026). FDA's concerns with unapproved GLP-1 drugs used for weight loss. Regulator fda.gov — accessed 20 October 2026 ↩
  45. Manning MC, Chou DK, Murphy BM, Payne RW, Katayama DS (2010). Stability of protein pharmaceuticals: an update. Pharmaceutical Research 27:544-575. Review doi:10.1007/s11095-009-0045-6 ↩
  46. Centers for Disease Control and Prevention (2024). Preventing Unsafe Injection Practices. Regulator cdc.gov — accessed 20 October 2026 ↩
  47. NHS (2025). Poisoning. Web page nhs.uk — accessed 22 October 2026 ↩
  48. Antonacci G, Bortignon E, Bolognesi M, Piano SS, Cadore A, Camuffo L, Venturini F, Faoro S, Favretto D, Romano A, Mengato D (2026). Hypoglycaemic coma induced by a falsified semaglutide product: a case report. European Journal of Hospital Pharmacy 33:486-489. Research article doi:10.1136/ejhpharm-2025-004656 ↩
  49. Thuisarts.nl (Nederlands Huisartsen Genootschap, NHG) (2024). Ik ga naar de huisarts: wat kan ik van tevoren doen en verwachten?. Web page thuisarts.nl — accessed 22 October 2026 ↩
  50. Department of Health, Victoria (Australia), Chief Health Officer (2026). Toxicity linked to unapproved peptide product labelled Retatrutide (health alert). Regulator health.vic.gov.au — accessed 22 October 2026 ↩
  51. KNMG (Royal Dutch Medical Association) (2024). Medisch beroepsgeheim: wat en waarom. Web page knmg.nl — accessed 20 October 2026 ↩
  52. NHS (England) (2026). Sepsis. Web page nhs.uk — accessed 20 October 2026 ↩
  53. NHS (England) (2023). Anaphylaxis. Web page nhs.uk — accessed 20 October 2026 ↩
  54. European Medicines Agency (2026). Medicines (search of centrally authorised medicines and EPARs). Regulator ema.europa.eu — accessed 20 October 2026